Human Genome Sciences:

Zymogenetic's PEG-Interferon lambda is being tested now in once-weekly and once-every-two week dosing schedules; the latter probably needs to work well for the drug to be competitive in the future. A more pressing matter for Zymogenetics and its investors today is the slow launch of its blood-clotting drug Recothrom. This stock won't get unstuck from the mud until the company fixes that problem.
Marty P. asks, "What are your favorite biotech stocks right now? Do you see a recovery on the horizon. Many of you might find this hard to believe, but yes, I'm generally optimistic about biotech. While the sector has certainly taken its share of the lumps in the past two months, biotech hasn't fared as poorly as the broader market. And I was very encouraged by the strong earnings reports from the big-cap stocks.
The economy is in a recession and the market may or may not be at a bottom. But biotech drugs should be seen by investors as being relatively recession-proof, since most of these drugs address serious and often fatal diseases. Likewise, if an Obama administration pushes to allow Medicare to negotiate for lower drug prices, I believe that most biotech drugs will not be adversely affected as much as many Big Pharma-style drugs for the reasons stated above. (I know I'll get a lot of arguments about cancer drug pricing.)
As for my favorite biotech stocks, I still favor the big-caps as the best way to play a sector recovery. For me, Gilead Sciences remains the tops, I also like the big Revlimid growth story in Celgene, especially now that it's price-to-earnings multiple has come down, and Genentech) because, well, it's Genentech and that doesn't need any more explanation. Plus, I still think a Roche takeover bid for well more than $89 a share happens.